Sulcona

Sulcona is a UK-based biotechnology company specializing in the development of a novel class of covalent small molecule therapeutics. The company's proprietary platform utilizes "Sulconas," which are sulfonyl-containing compounds designed to target traditionally "undruggable" proteins with high precision and stability. By leveraging advanced chemical biology and proteomics, Sulcona aims to create next-generation treatments for cancer and inflammatory diseases. The company is a spin-out from the University of Oxford and Imperial College London, focusing on expanding the reach of covalent drug discovery. Sulcona is currently in the pre-clinical stage, supported by leading venture investors such as Oxford Science Enterprises.